Physician profile
Gloria Lin
NPI 1861927964
$164,314.96
in general payments reported to CMS, 2019-2025
31 companies · $145K in 2025
The $145K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.06 · 2021: $526 · 2022: $2,302 · 2023: $3,987 · 2024: $13K · 2025: $145K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Travel and Lodging: $20K · Food and Beverage: $17K · Consulting Fee: $13K · Education: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,950.00 |
| Travel and Lodging | $20,286.86 |
| Food and Beverage | $16,948.64 |
| Consulting Fee | $12,868.75 |
| Education | $415.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $137,664.73 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $11,918.14 | 2021-2025 | Opzelura |
| Abbvie INC. | $2,230.24 | 2022-2025 | |
| Janssen Biotech, INC. | $2,004.40 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,792.03 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,094.89 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $924.27 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $903.70 | 2022-2024 | Vtama |
| Leo Pharma INC. | $795.36 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $709.57 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $619.55 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $511.21 | 2021-2025 | |
| Ucb, INC. | $489.18 | 2022-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $445.27 | 2022-2025 | |
| Organon LLC | $400.43 | 2025 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $373.59 | 2022-2025 | Otezla, Otezla |
| Almirall LLC | $298.80 | 2021-2025 | Seysara, Klisyri |
| Sun Pharmaceutical Industries INC. | $252.20 | 2022-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $226.77 | 2022-2025 | |
| Journey Medical Corporation | $123.71 | 2022-2025 | |
| Botanix Sb INC | $107.07 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $106.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $65.64 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.37 | 2025 | Jublia, Siliq, Cabtreo |
| Regeneron Pharmaceuticals, INC. | $28.66 | 2025 | Dupixent |
| Verrica Pharmaceuticals INC. | $25.34 | 2024 | Ycanth |
| Strata Skin Sciences, INC. | $25.24 | 2024 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $23.10 | 2024 | Valchlor |
| Epi Health, LLC | $19.89 | 2022 | |
| Genentech USA, INC. | $17.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.